{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:16:41Z","timestamp":1784744201287,"version":"3.55.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Perampanel, a new specific non-competitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist, has been recently approved in the United States and the European Union for the adjunctive treatment of focal seizures and primary generalized tonic\u2013clonic seizures associated with idiopathic generalized epilepsy. A positive relationship between plasma perampanel concentration and improvement in seizure control has been identified in regulatory trials, suggesting that therapeutic drug monitoring could be useful in optimizing clinical response in patients with epilepsy treated with perampanel. The development of a simple and broadly applicable method for measuring plasma perampanel concentrations is desirable to permit the use of TDM for this drug in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A high-performance liquid chromatographic method with ultraviolet detection for the quantitative determination of perampanel in small aliquots of human plasma (200 \u03bcL) has been developed and validated. Sample preparation involves a simple precipitation step followed by solvent evaporation. High-performance liquid chromatographic separation is achieved on 2 reverse-phase monolithic columns in sequence connected to an ultraviolet detector (320 nm), using as mobile phase water\/acetonitrile (60:40 vol\/vol) mixed with 1 mL\/L phosphoric acid, at a flow rate of 1.5 mL\/min. Promethazine hydrochloride is used as internal standard.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Calibration curves were linear over a perampanel concentration range of 25\u20131000 ng\/mL, with correlation coefficients equal or greater than 0.998 \u00b1 0.001 and a limit of quantitation set at 25 ng\/mL. Intra- and inter-day coefficients of variation did not exceed 7.4%, and the accuracy ranged from 96.4% to 113.3%. No interference was observed from commonly coprescribed drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The present assay is simple, specific, and cost effective with performance characteristics suitable for TDM use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000350","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T11:46:32Z","timestamp":1475840792000},"page":"744-750","source":"Crossref","is-referenced-by-count":35,"title":["Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma"],"prefix":"10.1097","volume":"38","author":[{"given":"Valentina","family":"Franco","sequence":"first","affiliation":[{"name":"Genomic and post-Genomic Center, C. Mondino National Neurological Institute;"},{"name":"Division of Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marchiselli","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Fattore","sequence":"additional","affiliation":[{"name":"Genomic and post-Genomic Center, C. Mondino National Neurological Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tartara","sequence":"additional","affiliation":[{"name":"Genomic and post-Genomic Center, C. Mondino National Neurological Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[{"name":"Genomic and post-Genomic Center, C. Mondino National Neurological Institute;"},{"name":"Division of Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14728222.2014.874416","article-title":"Targeting \u03b1-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy","volume":"18","author":"Citraro","year":"2014","journal-title":"Expert Opin Ther Targets."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14656566.2014.879572","article-title":"Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures","volume":"15","author":"Franco","year":"2014","journal-title":"Expert Opin Pharmacother."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, gender and concomitant antiepileptic drugs","volume":"38","author":"Patsalos","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bcp.12951","article-title":"Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials","volume":"82","author":"Majid","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","article-title":"Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies","volume":"55","author":"Kramer","year":"2014","journal-title":"Epilepsia"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2015.09.002","article-title":"Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes","volume":"117","author":"Kwan","year":"2015","journal-title":"Epilepsy Res."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/bmc.3463","article-title":"HPLC with fluorescence detection assay of perampanel, a novel AMPA receptor antagonist, in human plasma for clinical pharmacokinetic studies","volume":"29","author":"Mano","year":"2015","journal-title":"Biomed Chromatogr."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2014.12.018","article-title":"High-performance liquid chromatography-tandem mass spectrometry method for the determination of perampanel, a novel \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma","volume":"107","author":"Mano","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R12-20230814","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3764","article-title":"An inter-laboratory cross validation study for the determination of perampanel in human plasma by liquid chromatography assays","author":"Mano","year":"2016","journal-title":"Biomed Chromatogr."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:13:00Z","timestamp":1692051180000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000350","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}